×
About 2,990 results

ALLMedicine™ Tardive Dyskinesia Center

Research & Reviews  1,157 results

Atypical antipsychotics: Managing adverse effects.
https://doi.org/10.1111/ppc.12837
Perspectives in Psychiatric Care; Kameg B, Champion C

May 6th, 2021 - The purpose of this article is to provide an overview of common adverse effects and management strategies related to atypical antipsychotic use. Atypical antipsychotics are commonly prescribed. While effective, atypical antipsychotics are associat...

Protective role of endocannabinoid signaling in an animal model of haloperidol-induced ...
https://doi.org/10.1016/j.pbb.2021.173193
Pharmacology, Biochemistry, and Behavior; Röpke J, Ferreira-Vieira TH et. al.

May 2nd, 2021 - Tardive dyskinesia (TD) is a side effect associated with the long-term use of certain antipsychotics. Considering the modulatory role of the endocannabinoid system upon dopaminergic neurotransmission, the present study tested the hypothesis that i...

Improvement of Inpatient Psychiatric Facility Quality Reporting program measure: Screen...
https://doi.org/10.1016/j.japh.2021.04.010
Journal of the American Pharmacists Association : JAPhA; Leung JG, Owen A et. al.

May 1st, 2021 - Second-generation antipsychotics are associated with lower risks of extrapyramidal symptoms, including tardive dyskinesia. However, many second-generation antipsychotics are associated with metabolic adverse effects, including weight gain, impaire...

Comparison of Safety and Tolerability of Deutetrabenazine During Titration and Maintena...
https://doi.org/10.1017/S1092852920002643
CNS Spectrums; Wilhelm A, Anderson KE et. al.

Apr 30th, 2021 - Deutetrabenazine is approved to treat tardive dyskinesia (TD) in adults and is titrated weekly by 6 mg/day, from 12 to 48 mg/day, based on dyskinesia control and tolerability. This analysis compared the safety of deutetrabenazine during titration ...

Treatment of tardive dyskinesia: a review and update for dermatologists managing delusi...
https://doi.org/10.1080/09546634.2021.1892025
The Journal of Dermatological Treatment; Cheng C, Brownstone N et. al.

Mar 30th, 2021 - This article introduces to the dermatology provider two medications for the treatment of tardive dyskinesia (TD), which were the first medications approved by the US FDA specifically for the treatment of TD. In addition to describing these two new...

see more →

Guidelines  1 results

Revisiting the Abnormal Involuntary Movement Scale: Proceedings From the Tardive Dyskin...
https://doi.org/10.4088/JCP.17cs11959
The Journal of Clinical Psychiatry; Kane JM, Correll CU et. al.

May 9th, 2018 - To provide an historic overview of the Abnormal Involuntary Movement Scale (AIMS) in clinical trials of tardive dyskinesia (TD), with current recommendations for analyzing and interpreting AIMS data. Seven psychiatrists and 1 neurologist were sele...

see more →

Drugs  187 results see all →

Clinicaltrials.gov  1,459 results

Atypical antipsychotics: Managing adverse effects.
https://doi.org/10.1111/ppc.12837
Perspectives in Psychiatric Care; Kameg B, Champion C

May 6th, 2021 - The purpose of this article is to provide an overview of common adverse effects and management strategies related to atypical antipsychotic use. Atypical antipsychotics are commonly prescribed. While effective, atypical antipsychotics are associat...

Protective role of endocannabinoid signaling in an animal model of haloperidol-induced ...
https://doi.org/10.1016/j.pbb.2021.173193
Pharmacology, Biochemistry, and Behavior; Röpke J, Ferreira-Vieira TH et. al.

May 2nd, 2021 - Tardive dyskinesia (TD) is a side effect associated with the long-term use of certain antipsychotics. Considering the modulatory role of the endocannabinoid system upon dopaminergic neurotransmission, the present study tested the hypothesis that i...

Improvement of Inpatient Psychiatric Facility Quality Reporting program measure: Screen...
https://doi.org/10.1016/j.japh.2021.04.010
Journal of the American Pharmacists Association : JAPhA; Leung JG, Owen A et. al.

May 1st, 2021 - Second-generation antipsychotics are associated with lower risks of extrapyramidal symptoms, including tardive dyskinesia. However, many second-generation antipsychotics are associated with metabolic adverse effects, including weight gain, impaire...

Comparison of Safety and Tolerability of Deutetrabenazine During Titration and Maintena...
https://doi.org/10.1017/S1092852920002643
CNS Spectrums; Wilhelm A, Anderson KE et. al.

Apr 30th, 2021 - Deutetrabenazine is approved to treat tardive dyskinesia (TD) in adults and is titrated weekly by 6 mg/day, from 12 to 48 mg/day, based on dyskinesia control and tolerability. This analysis compared the safety of deutetrabenazine during titration ...

Benztropine mesylate - benztropine mesylate tablet-Chartwell RX, LLC.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c002005d-a478-48d4-b345-cb87edcb061f

Apr 29th, 2021 - Benztropine mesylate tablets are indicated for use as an adjunct in the therapy of all forms of parkinsonism. Useful also in the control of extrapyramidal disorders (except tardive dyskinesia-see PRECAUTIONS) due to neuroleptic drugs (e.g., phenot...

see more →

News  163 results

'Landmark' Schizophrenia Drug in the Wings? 
https://www.medscape.com/viewarticle/946727

Mar 1st, 2021 - A novel therapy that combines a muscarinic receptor agonist with an anticholinergic agent is associated with a greater reduction in psychosis symptoms compared with placebo, new research shows. In a randomized phase 2 trial comprised of nearly 200...

Fast Five Quiz: Schizophrenia Management in Adults
https://reference.medscape.com/viewarticle/933512_6

Aug 10th, 2020 - First-generation antipsychotics have a high rate of extrapyramidal side effects, including rigidity, bradykinesia, dystonias, tremor, and akathisia. Tardive dyskinesia —involuntary movements of the face and extremities — is another adverse effect ...

The ABCDs of treating tardive dyskinesia
https://www.mdedge.com/psychiatry/article/219775/schizophrenia-other-psychotic-disorders/abcds-treating-tardive-dyskinesia?channel=133
Jonathan R. Scarff, MD

Mar 31st, 2020 - Tardive dyskinesia (TD)—involuntary movement persisting for >1 month—is often caused by exposure to dopamine receptor–blocking agents such as antipsychotics. 1 The pathophysiology of TD is attributed to dopamine receptor hypersensitivity and upregu.

A 39-Year-Old Woman With Past Cocaine Use, Rash, and Seizure
https://reference.medscape.com/viewarticle/898695_4

Mar 12th, 2020 - Reports have documented reversal of tardive dyskinesia with steroids. Oxidative stress as an inducer of Tardive dyskinesia has also been implicated.[7] Thus, more research on tardive dyskinesia is indicated to better understand these phenomena. In...

Fast Five Quiz: Tardive Dyskinesia Differential Diagnosis
https://reference.medscape.com/viewarticle/923959_1

Feb 20th, 2020 - Tardive dyskinesia (TD) is a troubling side effect that may occur with long-term dopaminergic antagonist medications. TD manifests as involuntary movements of the tongue, lips, face, trunk, and extremities. It is most commonly seen in patients wit...

see more →

Patient Education  23 results see all →